A Phase III Study of Paclitaxel Via Weekly 1 Hour Infusion Versus Standard 3 Hour Infusion Every 3 Weeks With Herceptin (Trastuzumab) (NSC #688097) in the Treatment of Patients With/Without HER-2/Neu-Overexpressing Metastatic Breast Cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Paclitaxel (Primary) ; Trastuzumab
- Indications Advanced breast cancer; Breast cancer
- Focus Biomarker; Therapeutic Use
- 04 Jun 2013 Biomarkers information updated
- 15 Mar 2012 Additional lead trial centres identified as reported by ClinicalTrials.gov.
- 21 Jun 2011 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.